RecruitingEUCTR 2022-002369-14
Psilocybin-Assisted Therapy for Severe Addiction: Feasibility, Clinical Efficacy & (Neuro)cognitive Mechanisms.
This historical record does not confirm current site availability.
Historical research recordBelgium
Understand this study
What is this study about?
This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments. Check the source details below for country statuses and any transfer to CTIS.
- Listed locations
- BrusselsSee all locations and recruitment
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
What to know before participating
A point to clarify
This is historical registry information. What is the current study status and protocol?
Things to check before joining
Study start dateNot clearly listed
- Recruitment status
- Recruiting
- Enrollment listed in the registry
- Not clearly listed
- Sponsor
- CHU Brugmann
- Sponsor type
- Hospital / academic medical center
- Study type
- Biological
- Intervention type
- Biological
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- Belgium
- Age range
- Not clearly listed
- Official registry ID
- EUCTR 2022-002369-14
- Official title
Show the full official title
Psilocybin-Assisted Therapy for Severe Alcohol Use Disorder: Feasibility, Clinical Efficacy & (Neuro)cognitive Mechanisms.
Recruitment & locations
Currently recruitingA study may be recruiting, but some locations may no longer be accepting participants. Confirm availability with the research team.
Brussels
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is CHU Brugmann, a hospital or academic medical center.
Is this study still recruiting?
The registry lists this study as recruiting.
